Kiadis Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.06.16	DGAP-News: Kiadis Pharma N.V. (EQS Group)
21.06.16	Kiadis Pharma Appoints PCT as its Contract Manufacturing Organization in the United States (Businesswire)
02.06.16	Kiadis Pharma gibt Entscheidung zur Einreichung eines Antrags auf Marktzulassung von ATIR101™ bei Blutkrebs bei der Europäischen Arzneimittelagentur (EMA) bekannt (Businesswire)
02.06.16	DGAP-News: Kiadis Pharma N.V. (EQS Group)
02.06.16	Kiadis Pharma Announces Its Decision to File for Marketing Authorization with the European Medicines Agency (EMA) for ATIR101™ in Blood Cancers (Businesswire)
18.05.16	Kiadis Pharma Presents Multiple Sets of Data at the International Society for Cellular Therapy (ISCT) 2016 Annual Meeting (Businesswire)
17.05.16	Kiadis Pharma Notice of Annual General Meeting of Shareholders (Businesswire)
15.04.16	Kiadis Pharma announces Annual Results for the year ended 31 December 2015 (Businesswire)
07.04.16	Kiadis Pharma Proposes Robert Soiffer and Berndt Modig as Its New Supervisory Board Members (Businesswire)
04.04.16	Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101™ (Businesswire)
29.03.16	Kiadis Pharma to Host a Webcast of the Full Dataset on the Primary Endpoint of Its Single-Dose Phase II Trial with ATIR101™ (Businesswire)
14.03.16	Kiadis Pharma Satellite Symposium at 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (Businesswire)
19.02.16	Disclosure of Home Member State (Businesswire)
01.02.16	Kiadis Pharma and the Leukemia & Lymphoma Society Enter Partnership for the Development of ATIR101™ in ALL and AML Patients (Businesswire)
21.12.15	Kiadis Pharma Announces a Global Collaboration with the Thalassaemia International Federation (Businesswire)
09.12.15	Kiadis Pharma announces results of extraordinary general meeting of shareholders (Businesswire)
07.12.15	Kiadis Pharma presents an update on its Phase II trial with ATIR101™ at the American Society of Hematology 2015 Annual Meeting (Businesswire)
27.11.15	Kiadis Pharma Interim Management Statement for the nine months ended 30 September 2015 (Businesswire)
03.11.15	Data from Kiadis Pharma’s ongoing Phase II trial with ATIR101™ will be presented at the American Society of Hematology 2015 Annual Meeting (Businesswire)
20.10.15	Kiadis Pharma announces enrolment of first patient in its repeat-dosing Phase II clinical trial with ATIR101™ (Businesswire)
30.09.15	Kiadis Pharma announces initiation of a repeat-dosing Phase II clinical trial with ATIR101™ (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Kiadis Pharma N.V.

Aktien Top/Flop

Meistgelesene Nachrichten